Cancer Drug Discovery Breakthroughs
- The study, published initially as a news release from Brown University, focuses on the PI3K/AKT/mTOR pathway.
- Researchers discovered that the pathway operates with two distinct "sides" - one promoting cancer-relevant functions and another activating survival mechanisms.This nuanced understanding is critical because many existing cancer...
- The Brown University team, led by Taylor, identified specific molecular events that differentiate between the cancer-promoting and survival-enhancing functions of the PI3K/AKT/mTOR pathway.
New Cancer Research Reveals Pathway to More Targeted Therapies
Table of Contents
– Researchers at Brown University have identified a crucial mechanism within a cellular pathway frequently hijacked by cancer, possibly paving the way for more effective and targeted cancer treatments.
Understanding the PI3K/AKT/mTOR Pathway
The study, published initially as a news release from Brown University, focuses on the PI3K/AKT/mTOR pathway. This pathway is vital for cell growth, proliferation, and survival, but is often dysregulated in cancer, driving uncontrolled tumor development. A key challenge in targeting this pathway has been its dual role: while it can promote cancer cell growth,it also plays a protective role,helping cells survive stress.
Researchers discovered that the pathway operates with two distinct “sides” – one promoting cancer-relevant functions and another activating survival mechanisms.This nuanced understanding is critical because many existing cancer drugs targeting this pathway have failed in clinical trials due to triggering these protective survival responses, ultimately helping the tumor resist treatment.
The Discovery: Separating Cancer-Promoting and Survival Signals
The Brown University team, led by Taylor, identified specific molecular events that differentiate between the cancer-promoting and survival-enhancing functions of the PI3K/AKT/mTOR pathway. They found that certain signals within the pathway are more directly linked to tumor growth, while others are primarily responsible for protecting the cell from stress. This distinction was made possible through detailed analysis of cellular signaling networks.
“This helps point the way toward designing drugs that target the cancer-relevant side of the pathway without triggering survival pathways that protect the tumor,” said Taylor, the study’s first author. The research suggests that future therapies could be designed to selectively inhibit the pro-cancer aspects of the pathway, leaving the protective functions intact.
Implications for Drug Development
The findings have meaningful implications for the development of new cancer therapies. By understanding the specific molecular signals driving tumor growth versus those promoting survival,researchers can design drugs that are more precise and effective. This approach could potentially overcome the resistance issues that have plagued previous attempts to target the PI3K/AKT/mTOR pathway.
“We are excited to share this story because we were able to answer a number of open questions that are vital in basic biology and also have therapeutic implications,” the researchers stated.